Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28470958 | 0.76 | — | — | |
| SCHEMBL26622164 | 0.74 | — | — | |
| SCHEMBL27856493 | 0.74 | — | — | |
| SCHEMBL1859713 | 0.73 | TSHR (0.52) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL11375964 | 0.72 | MEN1 (0.35) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL29439973 | 0.72 | CYP4F2 (0.39) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL27905787 | 0.71 | — | — | |
| SCHEMBL4271852 | 0.69 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL27576178 | 0.69 | ALDH1A1 (0.38) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL14978154 | 0.67 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | SMN1; SMN2 3464/4885LMNA 3433/4885ALDH1A1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.